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background: Novel anticoagulants dabigatran, rivaroxaban and apixaban were designed not to require monitoring of the anticoagulation effect. 
There are clinical situations where such monitoring would be useful including bleeding situations, trauma, and thromboembolic event while on 
anticoagulation. At this point monitoring of these agents is under investigation. Thrombelastography (TEG) evaluates the viscoelastic properties of 
blood during coagulation. The clinical application of TEG in monitoring novel anticoagulant treatment is not yet well defined. The purpose of this in 
vivo study was to systematically evaluate the anticoagulant effect of the novel agents dabigatran, rivaroxaban and apixaban with TEG.
methods: Healthy male volunteers (n = 10) were given oral dabigatran 150 mg once, or rivaroxaban 20 mg, or apixaban 10 mg once. TEG 
parameters Reaction time R, angle of Alfa and Maximum Amplitude (MA) were measured at times 0, 2, 4, and 24 hours after intake of the 
anticoagulant agent. We applied Koalin TEG assay. The value of each parameter was compared to baseline measurement at time 0. Repeated 
measures ANOVA test was performed.
results: For dabigatran, Reaction time R was increased by 73% as compared to baseline (p < 0.008) by 2 hours after intake. Alfa was decreased 
by 8% at 2 hours (p < 0.008). MA was not significantly altered. For rivaroxaban, R was increased by 75% as compared to baseline at 2 hours 
after intake (p = 0.03). Alfa was decreased by 14% and MA was decreased by 6% at 2 hours after intake (p = 0.03 for both). For apixaban R 
was increased by 18% as compared to baseline (p < 0.05) at 4 hours after intake. The MA was decreased by 5% (p= 0.016) and alfa was not 
significantly altered.
conclusion: We have for the first time demonstrated that Thromelastograph has the potential of monitoring the novel anticoagulants. This 
technology is relatively easy to use on whole blood without need for specialized laboratory expertise. The reaction time R with Koalin assay is the 
most suitable TEG parameters for evaluation of the antithrombotic effect of the novel anticoagulants. Larger clinical studies are warranted for 
correlation of TEG findings and clinical outcomes.
